Phaim Pharma
PrivateLast Round
Convertible Debt
Apr 1, 2021
Company Overview
Phaim Pharma is a biotechnology company that develops curative treatments and diagnostic tools for autoimmune diseases, with a primary focus on Type 1 Diabetes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phaim Pharma Comparables
Compare Phaim Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Imcyse | 87% | |
| Ahead Therapeutics | 84% | |
| IM Therapeutics | 84% | |
Phaim Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 1, 2021 |
Phaim Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| British Business Bank | Convertible Debt |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Monthly visitors grew 45% MoM, from 901 to 1.3K.
- Apr 1, 2021
British Business Bank participated in the round.
Phaim Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Phaim Pharma's valuation, stock price, and market status.